Abbott announced new late-breaking data demonstrating use of its FreeStyle Libre system, continuous glucose monitoring (CGM) technology, is associated with significant reduction in hemoglobin A1c (HbA1c) levels for… read more.
Sun Pharmaceutical Industries announced further evidence of the long-term use and cost-effectiveness of Ilumya (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis. Long-term analyses of the phase III reSURFACE 1 and… read more.
LEO Pharma presented results from the Phase III PSO-LONG clinical trial comparing the efficacy and safety of twice-weekly Enstilar (calcipotriene and betamethasone dipropionate) foam, versus foam vehicle for… read more.
AbbVie announced new late-breaking IMMerge Phase IIIb open-label study head-to-head data showing superior rates of skin clearance for Skyrizi (risankizumab)to Cosentyx (secukinumab) at week 52 in psoriasis. Particularly,… read more.
Sun Pharmaceutical Industries announced further evidence of the long-term use and cost-effectiveness of Ilumya (tildrakizumab-asmn) in moderate-to-severe plaque psoriasis. Long-term analyses of the phase III reSURFACE 1 and… read more.
Novo Nordisk announced results from two real-world studies: EXPERT, which confirms the efficacy Ozempic (once–weekly semaglutide) demonstrated in the SUSTAIN clinical trial programme, and PATHWAY, which supports recommendations… read more.
New real-world data showed Trulicity (dulaglutide), from Eli Lilly, had significantly higher adherence and longer persistence compared to weekly injections of semaglutide or exenatide (BCise pen) in people… read more.
Merck Inc announced that the FDA has approved a supplemental New Drug Application (sNDA) for Recarbrio (imipenem, cilastatin, and relebactam) for the treatment of patients 18 years of… read more.
Eli Lilly and Company will present new data for Olumiant (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020) taking place June 3-6, 2020. Highlights from Olumiant… read more.
Bristol Myers Squibb announced results from the open-label switch period of Early AMPLE, a Phase IV exploratory biomarker study assessing the differences by which Orencia (abatacept) and another… read more.
Peter Mas-Mollinedo, CEO of ICR Ltd, joins Professor Rose Anne Kenny to discuss why vitamin D is so important to our immune system, why so many people are… read more.
Evofem Biosciences, Inc. announced that the FDA has approved Phexxi (lactic acid, citric acid and potassium bitartrate) vaginal gel for the prevention of pregnancy in females of reproductive… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
